

# Irritable Bowel Syndrome: Implications of Current Evidence for the Primary Care Physician

Supplement 2 to Volume 70, June 2003

SUPPLEMENT EDITOR:  
EDY E. SOFFER, MD  
CLEVELAND CLINIC

**N**EW DEVELOPMENTS and evidence relating to irritable bowel syndrome (IBS) recently prompted the American College of Gastroenterology (ACG) to issue a major evidence-based position statement on the management of this prevalent disorder. Like many position statements, however, it was for the most part written by specialists for specialists.

To explore implications of the new ACG position statement from a decidedly primary care perspective, the *Cleveland Clinic Journal of Medicine* convened a case-based roundtable discussion on IBS earlier this year. Our panel of primary care physicians and gastroenterologists aimed to discuss issues in the diagnosis and pharmacologic treatment of IBS that are most relevant to primary care physicians. The roundtable began with an overview of IBS by Dr. Kevin Olden, who served on the ACG task force that developed the position statement; his overview is reflected here in a short review article that sets the stage for the roundtable transcript that follows. The figures and tables within the transcript were developed by consensus of the panel.

## Contents

### Review article

|   |           |
|---|-----------|
| <b>Irritable bowel syndrome: . . . . .</b>                  | <b>S3</b> |
| <b>An overview of diagnosis and pharmacologic treatment</b> |           |
| Kevin W. Olden, MD  |           |

### Roundtable discussion

|  |           |
|--|-----------|
| <b>Irritable bowel syndrome: . . . . .</b>                   | <b>S8</b> |
| <b>New tools and insights for the primary care physician</b> |           |
| Case presentation . . . . .                                  | S8        |
| Screening: How much is enough? . . . . .                     | S9        |
| Other key considerations in the evaluation . . . . .         | S12       |
| When to refer . . . . .                                      | S13       |
| Treatment: General issues and approach . . . . .             | S14       |
| Factoring in depressive disorders . . . . .                  | S16       |
| Safety and the serotonin system . . . . .                    | S17       |
| Comfort levels with the newer agents . . . . .               | S17       |

## Disclosures

The following contributors to this supplement reported that they may have a relationship that, in the context of their contributions to this supplement, could be perceived as a potential conflict of interest:

**Kevin W. Olden, MD**, consultant—Novartis Pharmaceuticals and GlaxoSmithKline

**Edy E. Soffer, MD**, consultant—Impulse Dynamics

## Roundtable faculty



**Edy E. Soffer, MD**, Moderator  
Head, Center for GI Motility Disorders  
Department of Gastroenterology and  
Hepatology  
Cleveland Clinic Foundation  
Cleveland, Ohio



**Stephen Brunton, MD**  
Director of Faculty Development  
Stamford Hospital/Columbia University  
Family Practice Residency Program  
Stamford, Connecticut



**J. Harry Isaacson, MD**  
Vice Chairman, Department of General  
Internal Medicine  
Cleveland Clinic Foundation  
Cleveland, Ohio



**Kevin W. Olden, MD**  
Associate Professor of Medicine  
Division of Gastroenterology  
Mayo Clinic Scottsdale  
Scottsdale, Arizona



**Bo Shen, MD**  
Associate Staff  
Department of Gastroenterology and  
Hepatology  
Cleveland Clinic Foundation  
Cleveland, Ohio

## Acknowledgment

This supplement was supported by an educational grant from Novartis Pharmaceuticals Corporation.

The following contributors to this supplement reported that they have no relationships that, in the context of their contributions, could be perceived as a potential conflict of interest:

**Stephen Brunton, MD**

**J. Harry Isaacson, MD**

**Bo Shen, MD**

Copyright© 2003 The Cleveland Clinic Foundation.

The statements and opinions expressed in this supplement to the *Cleveland Clinic Journal of Medicine* are those of the authors and not necessarily of The Cleveland Clinic Foundation, its Board of Trustees, or Novartis Pharmaceuticals.

The *Cleveland Clinic Journal of Medicine* (ISSN 0891-1150) is published 12 times yearly by The Cleveland Clinic Foundation.

Subscription rates: U.S. and possessions: personal \$98; institutional \$124; single copy/back issue \$16. Foreign: \$124; single copy/back issue \$16. Institutional (mul-

tiplier rate) applies to libraries, schools, hospitals, and federal, commercial, and private institutions and organizations. Individual subscriptions must be in the names of, billed to, and paid by individuals.

*Postmaster address changes:* *Cleveland Clinic Journal of Medicine*, NA32, 9500 Euclid Avenue, Cleveland, OH 44195. Subscription orders, editorial, reprint, and production offices (same address): Phone (216) 444-2661; Fax (216) 444-9385; E-mail ccjm@ccf.org; World Wide Web address: <http://www.ccjm.org>

Printed in USA.

